Rybelsus Shortness of Breath: Causes, Warning Signs & What to Do

Rybelsus (semaglutide) is an oral GLP-1 receptor agonist licensed in the UK for type 2 diabetes mellitus. Whilst shortness of breath is not listed as a recognised adverse effect in the Summary of Product Characteristics, patients occasionally report breathlessness whilst taking this medicine. Understanding whether Rybelsus can cause respiratory symptoms, recognising serious warning signs, and knowing when to seek medical help are essential for safe use. This article examines the evidence, explores potential mechanisms, and provides practical guidance for patients and healthcare professionals managing breathlessness in individuals prescribed Rybelsus.

Can Rybelsus Cause Shortness of Breath?

Rybelsus (semaglutide) is an oral glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for the treatment of type 2 diabetes mellitus. Shortness of breath (dyspnoea) is not listed amongst the adverse effects in the Summary of Product Characteristics (SmPC) or patient information leaflet, and a causal association has not been established.

The mechanism by which GLP-1 receptor agonists work primarily involves enhancing glucose-dependent insulin secretion, suppressing glucagon release, and slowing gastric emptying. These actions do not directly affect respiratory function. However, gastrointestinal side effects—particularly nausea, vomiting, and abdominal discomfort—are very common with Rybelsus and may indirectly cause a sensation of breathlessness or chest tightness in some patients.

It is important to note that breathlessness in patients taking Rybelsus may be coincidental or related to underlying cardiovascular or respiratory conditions, which are prevalent in people with type 2 diabetes. Obesity, a common comorbidity, can also contribute to exertional dyspnoea.

Breathing difficulties can occur as part of hypersensitivity reactions to semaglutide, which are rare but documented in the SmPC. These warrant urgent medical assessment.

Patients experiencing new or worsening shortness of breath should not assume it is a benign side effect. A thorough clinical assessment is essential to exclude serious causes such as heart failure, pulmonary embolism, or respiratory infection. Any unexplained breathlessness warrants prompt medical evaluation.

Recognising Serious Breathing Problems While Taking Rybelsus

Whilst mild breathlessness may occasionally occur in the context of gastrointestinal upset, certain respiratory symptoms require urgent medical attention. Patients and healthcare professionals should be vigilant for red flag features that suggest serious underlying pathology rather than a medication-related side effect.

Seek immediate medical help (call 999 or attend A&E) if you experience:

• Sudden onset of severe breathlessness, particularly at rest

• Chest pain or tightness accompanying breathlessness

• Rapid or irregular heartbeat (palpitations)

• Swelling of the face, lips, tongue, or throat (potential anaphylaxis)

• Difficulty swallowing or speaking

• Wheeze or stridor (high-pitched breathing sound)

• Cyanosis (blue discolouration of lips or fingertips)

• Confusion, dizziness, or loss of consciousness

These symptoms may indicate serious conditions including acute coronary syndrome, pulmonary embolism, severe allergic reaction, or acute heart failure—all of which require emergency assessment and treatment.

Contact your GP or NHS 111 within 24 hours if you notice:

• Gradually worsening breathlessness over days or weeks

• Breathlessness that limits your usual daily activities

• Persistent cough, particularly if productive or blood-stained

• Ankle swelling or weight gain (possible fluid retention)

• Breathlessness when lying flat (orthopnoea)

People with type 2 diabetes have an increased cardiovascular risk, and new respiratory symptoms should always be investigated thoroughly. NICE guidance (NG106) recommends that patients with suspected heart failure should have natriuretic peptide testing (NT-proBNP) and echocardiography arranged promptly. For NT-proBNP levels >2000 pg/mL, echocardiography should be performed within 2 weeks, while levels between 400-2000 pg/mL warrant echocardiography within 6 weeks.

What to Do If You Experience Breathlessness on Rybelsus

If you develop shortness of breath whilst taking Rybelsus, a systematic approach to assessment and management is essential. Do not stop taking Rybelsus abruptly without medical advice, as this may affect your diabetes control.

Initial steps:

First, consider whether the breathlessness coincides with other symptoms. If you are experiencing significant nausea, vomiting, or abdominal bloating—common side effects of Rybelsus—these gastrointestinal symptoms may be contributing to a sensation of breathlessness or chest discomfort. Follow the SmPC administration instructions (taking Rybelsus with no more than 120ml of water on an empty stomach and waiting 30 minutes before eating) to ensure proper absorption; gastrointestinal effects often settle with time.

Monitor the pattern and severity of your symptoms. Note whether breathlessness occurs at rest or only with exertion, whether it is improving or worsening, and if any other symptoms are present. This information will be valuable for your healthcare professional.

If you develop signs of a severe allergic reaction (e.g., throat swelling, wheeze) or suspected pancreatitis (severe abdominal pain/vomiting), stop the medicine and seek urgent medical care.

Medical assessment:

Arrange a consultation with your GP or diabetes specialist nurse. They will conduct a thorough clinical assessment including:

• Detailed history of your symptoms and their temporal relationship to starting Rybelsus

• Examination of your cardiovascular and respiratory systems

• Review of your diabetes control and other medications

• Assessment for alternative causes of breathlessness

Depending on clinical findings, investigations may include blood tests (full blood count, renal function, thyroid function, natriuretic peptides), chest X-ray, electrocardiogram (ECG), and spirometry. If a serious cause is excluded and symptoms are mild, your doctor may suggest continuing Rybelsus with close monitoring, as gastrointestinal side effects often improve over time. Alternatively, dose adjustment or switching to an alternative diabetes medication may be considered.

Other Respiratory Side Effects Associated with Rybelsus

Beyond breathlessness, patients taking Rybelsus should be aware of other potential respiratory considerations, though these are generally uncommon.

Gastrointestinal-related respiratory symptoms:

The most frequent side effects of Rybelsus involve the gastrointestinal system. According to the SmPC, nausea and diarrhoea are very common (affecting more than 1 in 10 people), while vomiting is common (affecting up to 1 in 10 people). Severe nausea and vomiting can occasionally lead to aspiration risk, particularly in patients with gastroparesis or during anaesthesia/sedation. Gastro-oesophageal reflux, which may be exacerbated by delayed gastric emptying, can cause nocturnal cough or a sensation of chest tightness. These symptoms typically improve with time or dose adjustment.

Allergic and hypersensitivity reactions:

Whilst rare, hypersensitivity reactions to semaglutide have been reported. These may present with respiratory symptoms including wheeze, throat tightness, or difficulty breathing, often accompanied by skin rash, itching, or facial swelling. Anaphylaxis is extremely rare but constitutes a medical emergency requiring immediate treatment with intramuscular adrenaline.

Considerations in pre-existing respiratory disease:

There is limited specific data on Rybelsus use in patients with chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD) or asthma. However, GLP-1 receptor agonists do not have known direct effects on airway function. Patients with pre-existing breathlessness should discuss this with their prescriber before starting Rybelsus to establish a baseline and monitoring plan.

Thyroid considerations:

In animal studies, GLP-1 receptor agonists have been associated with thyroid C-cell tumours, though relevance to humans remains uncertain. Whilst thyroid pathology rarely presents with breathlessness, any neck swelling or difficulty swallowing should be reported to your doctor promptly.

Report any suspected side effects from Rybelsus via the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk or via the Yellow Card app).

Frequently Asked Questions